India Pharma Outlook Team | Wednesday, 10 June 2026
India may be preparing to offer fresh support to the pharmaceutical industry as it considers extending customs duty exemptions on key petrochemical imports.
The proposed duty relief for pharma raw materials comes at a time when drug manufacturers are facing rising input costs and supply chain uncertainties linked to geopolitical tensions in West Asia.
Industry stakeholders believe that extending the duty waiver could help stabilize production costs and ensure uninterrupted availability of essential medicines.
The government's review of the duty relief for pharma raw materials is particularly significant because several pharmaceutical ingredients, solvents, intermediates, and packaging materials depend on petrochemical-based inputs. Any increase in the cost of these materials directly impacts manufacturing expenses and profit margins for drugmakers.
According to reports, the government is evaluating whether the customs duty exemption on selected petrochemical products should continue beyond its current expiry date of June 30, 2026. The temporary relief was introduced earlier this year to help industries manage the impact of global supply disruptions and escalating costs caused by instability in West Asia.
The exemption currently covers around 40 petrochemical products that are widely used across multiple sectors, including pharmaceuticals, chemicals, plastics, textiles, and medical devices. Officials are reportedly assessing market conditions and supply chain risks before making a final decision on the extension.
Industry experts believe that maintaining the duty waiver for a longer period could provide much-needed support to manufacturers dealing with volatile raw material costs.
Also Read: The Evolving Role of India as a Talent Hub for Healthcare R&D
Petrochemical derivatives play a critical role in pharmaceutical manufacturing. They are used in the production of active pharmaceutical ingredient (API) intermediates, solvents, excipients, laboratory chemicals, and packaging materials.
When global crude oil prices rise or petrochemical supply chains face disruptions, pharmaceutical companies often experience higher procurement costs. These additional expenses can affect operational efficiency and reduce profitability.
An extension of customs duty relief would help lower import costs for essential raw materials, enabling manufacturers to better manage expenses while maintaining production levels. This is especially important for companies supplying large volumes of generic medicines both in India and international markets.
One of the key reasons behind the government's review is the ongoing geopolitical uncertainty in West Asia. The region plays an important role in global energy and petrochemical supply chains.
Any disruption in shipping routes, refinery operations, or petrochemical production facilities can create shortages and trigger price increases worldwide. Indian pharmaceutical companies remain vulnerable to these fluctuations because many of their raw materials are linked to petrochemical feedstocks.
Although the existing duty exemption has provided some relief, industry representatives have indicated that challenges related to logistics, availability of materials, and global pricing pressures continue to persist.
As a result, manufacturers are urging policymakers to continue supporting the sector until market conditions become more stable.
If the government decides to extend the duty waiver, the move could offer several benefits to pharmaceutical manufacturers:
The decision may be particularly beneficial for export-oriented pharmaceutical companies that compete in highly price-sensitive international markets. Lower input costs can help preserve competitiveness while supporting long-term growth.
However, experts caution that the exemption alone cannot completely offset the impact of rising global petrochemical prices. International market trends, freight costs, and supply availability will continue to influence overall manufacturing expenses.
The pharmaceutical industry is closely monitoring developments as policymakers evaluate the future of the customs duty relief program. While no official announcement has been made, the possibility of an extension has generated optimism among manufacturers facing ongoing cost pressures.
With supply chain risks still present and geopolitical uncertainties showing little sign of easing, an extension of the duty waiver could provide an important buffer for one of India's most strategically important industries.
The government's final decision is expected to depend on market conditions, global developments, and the broader objective of ensuring stable industrial growth while protecting critical sectors such as pharmaceuticals.
.jpg)
